
Guardian Pharmacy Services, Inc. Class A (($GRDN)) has held its Q3 earnings call. Read on for the main highlights of the call. Guardian Pharmacy Services delivered a strongly positive earnings
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| GRDN | Guardian Pharmacy Services, Inc. Class A | 48.84 | 21.29 | 77.28% |
| Name | Price | % Change | |
|---|---|---|---|
| $48.84 | +77.28% |

Guardian Pharmacy Services, Inc. Class A (($GRDN)) has held its Q3 earnings call. Read on for the main highlights of the call. Guardian Pharmacy Services delivered a strongly positive earnings

Bank of America Securities analyst Allen Lutz has reiterated their bullish stance on GRDN stock, giving a Buy rating today. Allen Lutz’s rating is based on Guardian Pharmacy Services’ strong

Reports Q3 revenue $371.1M, consensus $365.76M. “We are very pleased with our third-quarter performance, highlighted by strong resident and prescription growth. Absent the price reductions from the IRA, revenues would

Previous view $1.43B-$1.45B. Raises FY26 adjusted EBITDA view to $136M-$138M from $129M-$131M. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’

Guardian Pharmacy (GRDN) Services announced the acquisition of Van’s Institutional Pharmacy, an LTC pharmacy based in Martin, Tenn. The addition grows Guardian’s Tennessee operations to five pharmacies in Memphis, Shelbyville,

KeyBanc initiated coverage of Guardian Pharmacy (GRDN) with an Overweight rating and $52 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try

KeyBanc initiated coverage of Guardian Pharmacy (GRDN) with an Overweight rating and $52 price target The firm views Guardian as the “definitive leader” in long-term care pharmacy with structural advantages

Truist raised the firm’s price target on Guardian Pharmacy (GRDN) to $51 from $47 and keeps a Buy rating on the shares as part of a broader research note updating

Guardian Pharmacy Services, Inc. Class A ( ($GRDN) ) has provided an announcement. Guardian Pharmacy Services, Inc. entered into lock-up agreements on September 10, 2026 with its founders, executive officers

Analyst Allen Lutz of Bank of America Securities reiterated a Buy rating on Guardian Pharmacy Services, Inc. Class A, retaining the price target of $47.00. Allen Lutz has given his
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 31, 2027TBA | $3.19B | $0.45 | $392.88M | -0.26 | 41.39 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.